Act of emergency Tyr-D-Ala-Gly-Phe-Leu capsule enteroscopy in serious obscureovert gastrointestinal bleeding. Endoscopy ; Apr: . . Apostolopoulos P,Liatsos C,Gralnek IM,et al. Evaluation of capsule endoscopy in active,mildtomoderate,overt,obscure GI bleeding. Gastrointest Endosc ; Dec: . . PintoPais T,Pinho R,Rodrigues A,et al. Emergency singleballoon enteroscopy in overt obscure gastrointestinal bleeding: efficacy and safety. United European Gastroenterol J ; Dec: . Disclosure of Interest: None declaredP PREDICTING INFLAMMATORY PATHOLOGY AT CAPSULE ENTEROSCOPY: What’s the UTILITY OF A RAISED FAECAL CALPROTECTINC. Parker,C. Lamb,M. Robinson,J. Mansfield,M. Gunn Gastroenterology,Royal Victoria Infirmary,Newcastle upon Tyne,United KingdomContact Email Address: clare.e.parkerdoctors.net.uk Introduction: Faecal Calprotectin (FCP) is really a broadly utilised biomarker of gastrointestinal (GI) mucosal inflammation. Many capsule enteroscopy (CE) solutions are getting enhanced referrals of patients with abdominal symptoms combined with an elevated FCP (mgg) but standard gastroscopy,colonoscopy or radiology. There is certainly small information on using FCP levels as a screening tool for choosing individuals in whom CE will lead to a definitive diagnosis. Elevated FCP levels could indiscriminately drive investigations in endoscopy and imagingnegative patients who subsequently have regular findings at CE. We aimed to ascertain the incidence of inflammatory pathology on CE in patients using a raised FCP,and if a appropriate concentration on the biomarker could be identified as a screening tool to prevent unnecessary CE. Aims Strategies: A single centre retrospective review from the Newcastle upon Tyne Hospitals CE database was performed (Feb Feb. Patients PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25611386 with GI symptoms (abdominal discomfort,diarrhoea,bloating,vomiting,fat reduction) in addition to a raised FCP (mgg) were identified. Findings at CE regarded as to become inflammatory have been: erythema,ulceration,erosions and fissuring. Final results: patients had been identified with elevated FCP and GI symptoms. . (n) had inflammation identified by CE and in . (n) no inflammatory pathology was identified. The mean (SE) FCP was higher in individuals with proof of inflammation at CE in comparison to these with no inflammation: .mgg vs. mgg; p Stratifying patients according to FCP revealed that only . of patients (n) with a FCP of mgg had inflammatory findings at CE. This rose to . of patients (n) using a FCP of mgg,and . of sufferers (n) using a FCP mgg. A threshold of mgg FCP revealed a sensitivity of . to predict inflammation at CE,having a specificity of . . This FCP threshold had a adverse predictive worth of . ,and constructive predictive value of . for CE inflammation. Conclusion: In this compact retrospective analysis of a subgroup of sufferers referred for CE having a FCP of mgg the likelihood of identifying inflammatory pathology at CE elevated with rising FCP concentrations above mgg. A threshold of mgg offered a high negative predictive worth for CE inflammation and might be a helpful screening tool to reduce the requirement for CE in select patient groups. This retrospective evaluation must be confirmed in a bigger potential cohort. Disclosure of Interest: None declaredUnited European Gastroenterology Journal (S) P Role OF SECONDGENERATION COLON ENDOSCOPY FOR Complete GUT EVALUATION CAPSULEA Results: sufferers have been enrolled for the final investigation ( instances were excluded from further evaluation because of the capsule did not attain the colon). In patients a single or additional lesions previously missed by conv.
